State Street Corp Cuts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

State Street Corp decreased its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 12.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,371,271 shares of the company's stock after selling 337,262 shares during the quarter. State Street Corp owned about 3.35% of Nurix Therapeutics worth $53,282,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Amalgamated Bank increased its stake in Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company's stock worth $49,000 after acquiring an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock worth $54,000 after buying an additional 559 shares during the last quarter. Quarry LP boosted its stake in Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company's stock worth $56,000 after buying an additional 2,435 shares during the period. International Assets Investment Management LLC increased its position in Nurix Therapeutics by 1,098.4% during the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company's stock valued at $101,000 after acquiring an additional 4,119 shares during the last quarter. Finally, Quest Partners LLC raised its stake in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company's stock valued at $168,000 after acquiring an additional 1,312 shares during the period.

Insider Activity at Nurix Therapeutics

In related news, insider Christine Ring sold 5,760 shares of Nurix Therapeutics stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $22.23, for a total transaction of $128,044.80. Following the completion of the sale, the insider now owns 24,592 shares of the company's stock, valued at $546,680.16. The trade was a 18.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,368 shares of the company's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $57,542.40. Following the completion of the sale, the chief financial officer now directly owns 37,270 shares in the company, valued at $905,661. This trade represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,401 shares of company stock valued at $437,453 in the last three months. 7.20% of the stock is owned by insiders.

Nurix Therapeutics Price Performance

Shares of NRIX stock traded down $0.20 during mid-day trading on Thursday, hitting $20.04. 977,868 shares of the stock traded hands, compared to its average volume of 903,952. Nurix Therapeutics, Inc. has a 52-week low of $7.65 and a 52-week high of $29.56. The stock has a market cap of $1.42 billion, a P/E ratio of -6.89 and a beta of 2.11. The stock's fifty day moving average is $23.58 and its two-hundred day moving average is $22.28.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings data on Friday, October 11th. The company reported ($0.67) EPS for the quarter, hitting the consensus estimate of ($0.67). The firm had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. As a group, equities analysts forecast that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Analysts Set New Price Targets

NRIX has been the subject of a number of recent analyst reports. Jefferies Financial Group assumed coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They set a "buy" rating and a $41.00 price target for the company. BMO Capital Markets assumed coverage on Nurix Therapeutics in a research report on Friday, December 6th. They set an "outperform" rating and a $35.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. Oppenheimer boosted their target price on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an "outperform" rating in a research note on Wednesday, September 4th. Finally, Royal Bank of Canada dropped their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $30.35.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.